A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer

Lung Cancer

Volumn 43, Issue 3, 2004, Pages 329-333

  Agelaki, Sofia ^a   Veslemes, Marinos ^b   Syrigos, Kostas ^b   Palamidas, Filippos ^c   Polyzos, Aristidis ^b   Papakotoulas, Pavlos ^d   Kentepozidis, Nikolaos ^a   Milaki, Georgia ^a   Tzanakis, Nikolaos ^a   Kouroussis, Charalambos ^a   Vamvakas, Lambros ^a   Georgoulias, Vassilis ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c SISMANOGLIO HOSPITAL   (Greece)

^d THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Docetaxel; Gemcitabine; Pretreated SCLC

Indexed keywords

DOCETAXEL; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TOXICITY; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 10744231578     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.08.031     Document Type: Article

References (22)

1. Murren J, Glatstein E, Pass HI. Small cell lung cancer. In: Devita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. 6th ed. Lippincott Williams and Wilkins; 2001. 31(3): 983-1018.
2. Giaccone G., Ferrati P., Donadio M., Testore F., Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 23(11):1987;1697-1699.
3. Vincent M., Evans B., Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol. 21(1):1988;45-48.
4. Simon G.R., Wagner H. Small cell lung cancer. Chest. 123:2003;259S-271S.
5. Spiro S.G., Porter J.C. Lung cancer-where are we today? current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med. 166(9):2002;1166-1196.
6. Ardizzoni A., Manegold C., Debruyne C., Gaafar R., Buchholz E., Smit E.F.et al. European Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res. 9:2003;143-150.
7. Sandler A. Irinotecan plus cisplatin in small-cell lung cancer. Oncology (Huntingt) 2002; 16(9, Suppl 9): 39-43.
8. Kwong M.S., Bleickardt E., Murren J.R. Camptothecin and taxane regimens for small-cell lung cancer. Oncology (Huntingt). 16(9, Suppl 9):2002;33-38.
9. Hesketh P.J., Crowley J.J., Burris H.A. III, Williamson S.K., Balcerzak S.P., Peereboom D.et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group phase II trial. Cancer J Sci Am. 5(4):1999;237-241.
10. Smyth J.F., Smith I.E., Sessa C., Schoffskii P., Wanders J., Franklin H.et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The early Clinical Trials Group of the EORTC. Eur J Cancer. 30A(8):1994;1058-1060.
11. Nakamura H., Azuma M., Miyagi K., Teruya S., Touyama M., Ishimine T.et al. A pilot study of docetaxel (TXT) as salvage chemotherapy in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 20:2001;280b. (2872 abstract).
12. Cormier Y., Eisenhauer E., Muldal A., Gregg R., Ayoub J., Goss G.et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 5(3):1994;283-285.
13. Masters G.A., DeClerk L., Blanke C., Sandler A., DeVore R., Miller K.et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol. 21(8):2003;1550-1555.
14. van der Lee I., Smit E.F., van Putten J.W., Groen H.J., Schlosser N.J., Postmus P.E.et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol. 12(4):2001;557-561.
15. Georgoulias V., Kouroussis C., Androulakis N., Kakolyris S., Dimopoulos M.A., Papadakis E.et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol. 17:1999;914-920.
16. Kosmas C., Tsavaris N., Mylonakis N., Kalofonos H. An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer. Crit Rev Oncol Hematol. 45:2003;265-275.
17. Rebattu P., Quantin X., Ardiet C., Morere J.F., Azarian M.R., Schuller-Lebeau M.P.et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer. 33:2001;277-287.
18. Mavroudis D., Alexopoulos A., Malamos N., Ardavanis A., Kandylis C., Stavrinidis E.et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. Oncology. 64:2003;207-212.
19. Miller A.B., Hoogstraten B., Staguet M., Winkler A. Reporting results of cancer research. Cancer. 47:1981;207-214.
20. Gehan E.A. The determination of the number of patients required in a follow-up trial of a new chemotherapy agent. J Chronic Dis. 13:1961;346-353.
21. Schuette W. Chemotherapy as treatment of primary and recurrent small cell lung cancer. Lung Cancer. 33(Suppl 1):2001;S99-S107.
22. Domine M., Gonzalez Larriba J., Morales S., Gómez R.G., Isla D., Terassa S.et al. Gemcitabine and paclitaxel as second line treatment in small cell lung cancer (SCLC). A multicentric phase II study. Proc Am Soc Clin Oncol. 20:2001;317a. (1263 abstract).